Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Growth in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 56,970 shares, an increase of 53.3% from the February 26th total of 37,152 shares. Approximately 5.9% of the shares of the stock are short sold. Based on an average daily volume of 276,289 shares, the short-interest ratio is presently 0.2 days.

Bluejay Diagnostics Stock Down 1.0%

Shares of NASDAQ:BJDX opened at $1.96 on Friday. The company’s fifty day moving average is $2.47 and its 200 day moving average is $4.73. The stock has a market cap of $1.90 million, a PE ratio of 0.00 and a beta of 0.72. Bluejay Diagnostics has a 52 week low of $1.70 and a 52 week high of $40.80.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Friday, March 6th. The company reported $3.23 earnings per share for the quarter.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent filing with the SEC. Institutional investors own 18.47% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Bluejay Diagnostics has an average rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.